Category Archives: Public Policy

Latest From Public Policy

Universities Express Concerns About Recently Passed House “Innovation Act”

Earlier this month, the House passed the Innovation Act (H.R. 3309), which seeks to address abuses of the U.S. patent litigation system. While the goal is commendable, the bill is overly broad in important respects and if enacted into law would produce unintended and unknowable consequences for innovators who rely on the patent system to fund and protect their inventions. The U.S. Senate is now developing similar legislation, the Patent Transparency and Improvement Act of Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,

VIDEO: Public Policies to Promote the Innovation Economy

SBIR Reauthorization Moves Forward

What can lawmakers do to make the US more competitive globally and encourage investment in groundbreaking R&D companies? Earlier today, the Coalition of Small Business Innovators held a forum at the National Press Club to discuss proposals that would do just that. Moderated by Paul Stimers, a partner with K&L Gates, the panel included Doug Doerfler, president and CEO of MaxCyte, Ed Mathers, a partner with venture capital firm New Enterprise Associates, Katherine Hamilton, policy Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , ,

FDA Check-Up: Drug Development and Manufacturing Challenges

Paul Hastings

I have over 27 years of experience in the biotechnology and pharmaceutical industry. My current company, OncoMed Pharmaceuticals, is working at the cutting edge of oncology research, focused on antibodies that target a specific set of cells within tumors, known as tumor initiating cells, that drive the growth of the tumor and can differentiate into various cell types within the tumor. Currently, we have five products in clinical development in over 13 completed or ongoing Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

Innovation Act Passed By House

House

The Innovation Act (H.R. 3309), which is intended to reduce frivolous patent-related litigation, was passed by the House today. As we’ve noted, BIO does not support the bill in its current form, which would ultimately undermine biotech research and innovation by making it more difficult for patent holders with legitimate claims to protect their intellectual property. A number of Representatives offered amendments to the bill, several of which BIO supported. These amendments address serious shortcomings with the bill, Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Innovation Act Threatens Biotech Innovation

AB23475

BIO has grave concerns regarding the Innovation Act (H.R. 3309), as reported by the House Judiciary Committee. The Innovation Act was introduced with the goal of furthering patent system reform, particularly with respect to patent-related litigation. We support increased transparency and oppose abusive litigation tactics. However, provisions in the Act remain overly broad in important respects and, if ultimately enacted, would continue to result in too many unintended and unknowable consequences for innovators who rely on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , ,